GLPG1690 halts disease progression in IPF patients
(WorldNews Belgium)

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial Forced vital capacity (FVC) in lungs stabilized over the 12-week treatment period, placebo arm showed expected decline Functional respiratory imaging (FRI) confirms FVC data with statistical significance GLPG1690 was generally well tolerated First autotaxin inhibitor to show effect in IPF patient trial GLPG1690 expected to progress to late stage trial Webcast presentation of the results to be held tomorrow 10 August, 14.00 CET/8 AM EDT, +32 2 404 0659, access code 2084135; more call number info further down Mechelen, Belgium; 9 August 2017; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG)...